Dr. Lal Path Labs Ltd.

rs 53

iagnostics India’s Leading & Trusted Diagnostics Company 141 Mn patients serviced in last 5 years 53 NABL & 2 CAP accredited Labs 7,700+ Patient Service Centers (PSC’s) 4,800+ Pathology, Radiolog

12%

Radiology tests & Panels; Comprehensive Test menu 312 Labs; Geographically spread-out network 12% FY26 Revenue Growth 44% ROCE Excl. Cash & Investments 280%* Dividend for FY25-26 AA+ Stab

44%

Comprehensive Test menu 312 Labs; Geographically spread-out network 12% FY26 Revenue Growth 44% ROCE Excl. Cash & Investments 280%* Dividend for FY25-26 AA+ Stable Credit Rating# As on

280%

Geographically spread-out network 12% FY26 Revenue Growth 44% ROCE Excl. Cash & Investments 280%* Dividend for FY25-26 AA+ Stable Credit Rating# As on March 31, 2026 * Adjusted for Bonus I

28%

l items (Rs. Cr.) Patients(Mn) Samples(Mn) SwasthFitTM Contribution 703 187 132 7.4 23.6 28% 603 169 115 6.8 20.9 26% Gr% 16.6% 10.5% 15.1% 8.2% 12.9% +2% 5 FY26 Performance Ove

26%

) Samples(Mn) SwasthFitTM Contribution 703 187 132 7.4 23.6 28% 603 169 115 6.8 20.9 26% Gr% 16.6% 10.5% 15.1% 8.2% 12.9% +2% 5 FY26 Performance Overview Revenue (Rs. Cr.) EBITD

16.6%

(Mn) SwasthFitTM Contribution 703 187 132 7.4 23.6 28% 603 169 115 6.8 20.9 26% Gr% 16.6% 10.5% 15.1% 8.2% 12.9% +2% 5 FY26 Performance Overview Revenue (Rs. Cr.) EBITDA before exc

10.5%

wasthFitTM Contribution 703 187 132 7.4 23.6 28% 603 169 115 6.8 20.9 26% Gr% 16.6% 10.5% 15.1% 8.2% 12.9% +2% 5 FY26 Performance Overview Revenue (Rs. Cr.) EBITDA before exceptiona

15.1%

tTM Contribution 703 187 132 7.4 23.6 28% 603 169 115 6.8 20.9 26% Gr% 16.6% 10.5% 15.1% 8.2% 12.9% +2% 5 FY26 Performance Overview Revenue (Rs. Cr.) EBITDA before exceptional items

8.2%

ntribution 703 187 132 7.4 23.6 28% 603 169 115 6.8 20.9 26% Gr% 16.6% 10.5% 15.1% 8.2% 12.9% +2% 5 FY26 Performance Overview Revenue (Rs. Cr.) EBITDA before exceptional items (Rs.

12.9%

tion 703 187 132 7.4 23.6 28% 603 169 115 6.8 20.9 26% Gr% 16.6% 10.5% 15.1% 8.2% 12.9% +2% 5 FY26 Performance Overview Revenue (Rs. Cr.) EBITDA before exceptional items (Rs. Cr.)

2%

3 187 132 7.4 23.6 28% 603 169 115 6.8 20.9 26% Gr% 16.6% 10.5% 15.1% 8.2% 12.9% +2% 5 FY26 Performance Overview Revenue (Rs. Cr.) EBITDA before exceptional items (Rs. Cr.) PAT b

“Ved Prakash Goel, Group CFO & CEO – International Business said: “Our FY26 performance underscores the resilience of our business model, delivering revenue growth of 12.2% driven by sample volume growth and a favorable test mix.”

“Sovaaka is not just an addition to our portfolio; it represents a foray into 'AI-powered Precision Health Screening.' As we enter FY27, our focus remains on accelerating organic growth and medical excellence to deliver long-term value for our stakeholders”.”

““We delivered a strong performance in Q4 and FY26, driven by healthy volume growth and an improved test mix, while maintaining a calibrated pricing approach.”

“In FY26 & FY25, DLPL collected and processed approximately 94.5 million samples and 85.6 million samples from 30.3 million and 28.8 million patients, respectively.”

Executive Chairman said

1

Chief Executive Officer said

1

UNLEASHING DIGITAL TRANSFORMATION

1

For further information please contact

1

Executive Chairman said

“India’s healthcare landscape is witnessing an emerging trend, moving from episodic care to a wellness-oriented diagnostic model. We are seeing a clear rise in the prevalence of chronic or non-communicable diseases and an aging population, both of which demand a more proactive approach to early detection and preventive health. At Dr. Lal PathLabs, our purpose remains rooted in bridging the access gap with reliable, technology-enabled diagnostics at scale. In parallel, the wider healthcare ecosystem is expanding, with hospitals adding new infrastructure and capabilities. Diagnostics usually grows alongside this expansion, and often ahead of it. We find that this opens up opportunities for stronger integration, better linkages and expansion of super specialised testing over time. As the broader healthcare ecosystem expands, we are ideally positioned to scale alongside. By integrating scale with digital innovation and higher-value testing, we remain committed to delivering sustainable val

Chief Executive Officer said

Commenting on the performance, Mr. Ved Prakash Goel, Group CFO & CEO – International Business said: “Our FY26 performance underscores the resilience of our business model, delivering revenue growth of 12.2% driven by sample volume growth and a favorable test mix. On the operational side, we successfully executed our expansion plan for the year, adding 14 new laboratories and more than 1100 collection centers. A significant highlight this quarter was hosting Medllumina 2026, a first-of-its-kind international medical conference from Dr. Lal PathLabs. This landmark event brought together clinicians and global thought 'New Era of leaders to deliberate on the Diagnostics,' specifically focusing on high-complexity domains. This initiative underscores our position as a vital clinical partner, deeply integrated into the precision medicine ecosystem. An important milestone of our strategic journey has been the launch of Sovaaka, our flagship brand in the premium wellness space. Sovaaka is not j

UNLEASHING DIGITAL TRANSFORMATION

DRIVING EFFICIENCY & ELEVATING CUSTOMER EXPERIENCE Operations • GenAl & curated healthcare models managing interactions • 90% queries handled by bots with lower drop rates • Automation of workflows Consumers Medical • Unified Communication Engine • WhatsApp as forefront communication channel • Guaranteed delivery with fallback mechanism • AI powered SEO engine for Organic discovery • Smart Culture Reporting: Advancing Quality through Data- Driven Reporting • Algorithms for Relationship Establishment in Solid Organ Transplantation • Complement Testing : Advancing Diagnosis & Precision Therapy through Validation & Verification IT Infrastructure - Al-ready compute environment for diagnostics & predictive analytics 25 Cyber Security Capability Extended Detection & Response Security Operations Center Software Security Threat Intelligence Data Loss Prevention • SASE - Secure Access Service Edge, • EDR - Endpoint Detection & Response • Cloud Native SIEM/SOAR for AI- driven security analytics

For further information please contact

Ved Goel Dr. Lal PathLabs Limited Tel: +91 124 301 6500 Fax: +91 124 423 4468 E-mail: ved.goel@lalpathlabs.com Siddharth Rangnekar / Nishid Solanki CDR India Tel: +91 22 66451209 / 1221 Fax: +91 22 66451213 Email: siddharth@cdr-india.com / nishid@cdr-india.com 29 Thank You 30